Aurobindo Pharma Past Earnings Performance

Past criteria checks 4/6

Aurobindo Pharma's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 5.1% per year. Aurobindo Pharma's return on equity is 9.8%, and it has net margins of 9.9%.

Key information

-3.6%

Earnings growth rate

-3.6%

EPS growth rate

Pharmaceuticals Industry Growth	17.5%
Revenue growth rate	5.1%
Return on equity	9.8%
Net Margin	9.9%
Next Earnings Update	30 May 2024

Recent past performance updates

Recent updates

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02

These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well

Nov 27

Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Nov 10

Here's Why Shareholders May Want To Be Cautious With Increasing Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Pay Packet

Aug 19

Aurobindo Pharma's (NSE:AUROPHARMA) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 15

Revenue & Expenses Breakdown
Beta

How Aurobindo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:AUROPHARMA Revenue, expenses and earnings (INR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	278,947	27,705	38,823	0
30 Sep 23	269,500	23,254	38,143	0
30 Jun 23	254,700	19,777	37,278	0
31 Mar 23	248,554	19,275	36,560	0
31 Dec 22	241,918	19,977	36,478	0
30 Sep 22	237,869	21,112	35,950	0
30 Jun 22	239,894	23,987	35,854	0
31 Mar 22	234,555	26,482	35,751	0
31 Dec 21	236,476	28,676	35,746	0
30 Sep 21	240,103	52,109	35,865	0
30 Jun 21	245,518	53,217	36,395	0
31 Mar 21	247,746	53,348	36,576	0
31 Dec 20	249,316	53,831	36,591	0
30 Sep 20	244,617	31,421	35,761	0
30 Jun 20	235,787	29,757	34,414	0
31 Mar 20	230,985	28,451	33,333	0
31 Dec 19	222,323	25,666	32,224	0
30 Sep 19	216,070	25,733	30,744	0
30 Jun 19	207,579	25,449	29,226	0
31 Mar 19	195,636	23,647	27,389	0
31 Dec 18	183,834	23,078	25,632	0
30 Sep 18	174,246	21,906	24,541	0
30 Jun 18	171,091	23,603	23,473	0
31 Mar 18	164,630	24,232	22,414	0
31 Dec 17	159,381	24,271	20,903	0
30 Sep 17	154,903	24,107	19,953	0
30 Jun 17	148,279	22,352	19,032	0
31 Mar 17	149,334	23,017	18,451	0
31 Dec 16	151,565	22,809	17,799	0
30 Sep 16	147,559	22,466	17,359	0
30 Jun 16	143,446	20,945	16,823	0
31 Mar 16	138,162	20,251	16,019	0
31 Dec 15	133,249	18,230	28,438	894
30 Sep 15	129,956	16,724	27,775	894
30 Jun 15	125,433	15,928	26,938	894
31 Mar 15	121,340	15,758	13,548	0
31 Dec 14	112,825	16,738	17,756	624
30 Sep 14	102,756	17,069	16,210	624
30 Jun 14	93,109	15,697	14,800	624
31 Mar 14	81,002	11,729	13,273	624
31 Dec 13	73,736	7,797	12,261	423
30 Sep 13	67,900	4,540	11,795	423
30 Jun 13	63,736	4,414	11,506	423

Quality Earnings: AUROPHARMA has high quality earnings.

Growing Profit Margin: AUROPHARMA's current net profit margins (9.9%) are higher than last year (8.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AUROPHARMA's earnings have declined by 3.6% per year over the past 5 years.

Accelerating Growth: AUROPHARMA's earnings growth over the past year (38.7%) exceeds its 5-year average (-3.6% per year).

Earnings vs Industry: AUROPHARMA earnings growth over the past year (38.7%) exceeded the Pharmaceuticals industry 23.1%.

Aurobindo Pharma Past Earnings Performance

Past criteria checks 4/6

Key information

Recent past performance updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Full year 2023 earnings: EPS misses analyst expectations

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹956

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 8.2% to ₹721

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before March 3, 2023

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Aurobindo Pharma Limited Announces Completion Of US FDA Inspection At Unit IX - Reg

Consensus EPS estimates fall by 15%

Price target decreased to ₹621

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Insider recently sold ₹11m worth of stock

Insider recently sold ₹2.7m worth of stock

Aurobindo Pharma Limited (NSEI:AUROPHARMA) completed the acquisition of 34% stake in GLS Pharma Ltd from Suresh and Sunita Pathak.

Full year 2022 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc. Announces Settlement with Aurobindo to Resolve AUSTEDO® (deutetrabenazine) Patent Dispute

Consensus EPS estimates fall by 11%

Price target decreased to ₹734

Aurobindo Pharma Limited Announces Fourth Interim Dividend for the Financial Year 2021-22, Payable on or Before June 15, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Domestic formulation business of Veritaz Healthcare from Veritaz Healthcare Limited for INR 1710 million.

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Business and certain assets of Veritaz Healthcare Limited for 1710 million.

Blackstone Reportedly Closing in on Aurobindo's Injectables Business

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Insider recently sold ₹2.4m worth of stock

Revenue & Expenses Breakdown
Beta